Semaglutide for tobacco use disorder (nicotine dependence)

Clinical

AP Staff

August 5, 2000

References

World Health Organisation. Tobacco Geneva, Switzerland: World Health Organisation. 2025. At: www.who.int/news-room/fact-sheets/detail/tobacco
Addiction Expert Group. Overview of tobacco smoking and nicotine dependence. 2023. Melbourne (AU): Therapeutic Guidelines Ltd. At: www.tg.org.au
US Centers for Disease Control and Prevention. Smoking Cessation: Fast Facts US: US Centers for Disease Control and Prevention. 2024 At: www.cdc.gov/tobacco/php/data-statistics/smoking-cessation/index.html#:~:text=the%20past%20year.-,Less%20than%201%20in%2010%20adults%20who%20smoke%20cigarettes%20succeed,smoking%20in%20the%20past%20year
Conley M. Five things to know about GLP-1s and addiction US: Standford Medicine. 2023. At: https://med.stanford.edu/news/insights/2025/04/ozempic-addiction-glp-1s-mounjaro-lembke.html
Wang W, Volkow N, Berger N, et al. Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: target trial emulation using real-world data. Ann Intern Med 2024;177(8):1016–27.
Popovic D, Patoulias D, Koufakis T, et al. Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire! Expert Rev Clin Pharmacol. 2024;17(11):1009–12.
Australian Medicines Handbook online [Internet]. Doxycycline. 2025. Adelaide (AU): Australian Medicines Handbook Pty Ltd. At: https://amhonline.amh.net.au/auth

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

What motivated you to seek election as the next PSA National President?

What do you hope to achieve as PSA President?

Why do you feel this is such a pivotal moment for PSA and the profession?

What are the major challenges pharmacists are facing right now?

How do you see the profession evolving in 5 years?

How have your background and previous experiences shaped your views of the profession?

Case scenario

Learning objectives

Introduction

Aetiology and pathophysiology

Clinical features

Diagnosis, differential diagnosis and prognosis

Management and treatment

Knowledge to practice

Conclusion

Case scenario continued

Key points

References

Our authors

Our reviewer

Conflict of interest declaration

Wrong-patient supply leads to hospital admission

Labelling and selection errors

A stronger incident-reporting culture

Building a career in incident management

ALERT 1: Potential risk of suicidal thoughts

What does the product warning say?

What products are affected by this alert?

What should pharmacists do?

ALERT 2: Tirzepatide (Mounjaro) and contraception

Is it just tirzepatide (Mounjaro)?

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

What motivated you to seek election as the next PSA National President?

What do you hope to achieve as PSA President?

Why do you feel this is such a pivotal moment for PSA and the profession?

What are the major challenges pharmacists are facing right now?

How do you see the profession evolving in 5 years?

How have your background and previous experiences shaped your views of the profession?

Case scenario

Learning objectives

Introduction

Aetiology and pathophysiology

Clinical features

Diagnosis, differential diagnosis and prognosis

Management and treatment

Knowledge to practice

Conclusion

Case scenario continued

Key points

References

Our authors

Our reviewer

Conflict of interest declaration

Wrong-patient supply leads to hospital admission

Labelling and selection errors

A stronger incident-reporting culture

Building a career in incident management

ALERT 1: Potential risk of suicidal thoughts

What does the product warning say?

What products are affected by this alert?

What should pharmacists do?

ALERT 2: Tirzepatide (Mounjaro) and contraception

Is it just tirzepatide (Mounjaro)?

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

**ALERT 2: Tirzepatide (Mounjaro) and contraception**

**ALERT 2: Tirzepatide (Mounjaro) and contraception**

**ALERT 2: Tirzepatide (Mounjaro) and contraception**